<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113753">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622348</url>
  </required_header>
  <id_info>
    <org_study_id>3100-202</org_study_id>
    <nct_id>NCT01622348</nct_id>
  </id_info>
  <brief_title>Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate different dose levels of IMO-3100 compared to
      placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, tolerability and treatment effect of different dose levels of
      IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe
      plaque psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine of mean epidermal thickness at End-of-Treatment (EOT) compared to pre-treatment (Day 1) through biopsy evaluation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Biopsies will be performed at Day 1 and EOT for comparison analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean focal psoriasis severity at EOT compared to pre-treatment. Mean percent reduction (improvement) in Psoriasis Area Severity Index at EOT compared to Day 1.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Psoriasis Area Severity Index (PASI) will be compared at End of Treatment (EOT) to pre-treatment (Day 1)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Actively Extending Plaque Psoriasis</condition>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline for Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMO-3100 at 0.16 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMO-3100 at 0.32 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-3100</intervention_name>
    <description>IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection</description>
    <arm_group_label>IMO-3100 at 0.16 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline for Injection</intervention_name>
    <description>Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-3100</intervention_name>
    <description>IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection</description>
    <arm_group_label>IMO-3100 at 0.32 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is age 18 to 70 years, inclusive;

          -  Completes the informed consent procedure (see Section 15.3), including signing and
             dating the informed consent form;

          -  Has moderate to severe plaque psoriasis meeting the criteria specified above;

          -  Female subjects must have a negative pregnancy test at screening and on Day 1 prior
             to start of treatment;

          -  Female subjects of childbearing potential (see Section 8.4.1) and male subjects who
             have partners of childbearing potential must agree to use effective birth control
             (contraception; see Section 8.4.1) from Screening through the treatment period and
             for four (4) weeks after the last injection of study drug.

        Exclusion Criteria:

          -  Has known hypersensitivity to any oligodeoxynucleotide;

          -  Is nursing;

          -  Has body weight &lt; 50 kg;

          -  Has BMI &gt; 34.9 kg/m2;

          -  Regularly consumes &gt; 3 drinks of alcoholic beverages (beer, wine, or distilled
             spirits) per day;

          -  Has a positive test for antibody to human immunodeficiency virus (HIV-1 or -2) or
             hepatitis C virus;

          -  Has a positive test for hepatitis B surface antigen (HBsAg);

          -  Has at screening safety laboratory tests meeting one or more of the following
             criteria:

          -  hemoglobin &lt; 10.5 g/dL

          -  white blood cell count &lt; 4,000 cells/mm3

          -  absolute neutrophil count (ANC) &lt; 1500/mm3

          -  platelet count &lt; 100,000/mm3

          -  alanine transaminase (ALT; SGPT) &gt; 1.5x ULN

          -  aspartate transaminase (AST; SGOT) &gt; 1.5x ULN

          -  serum total bilirubin &gt; 1.4x ULN

          -  serum creatinine &gt; 1.3x ULN;

          -  Has a history of allogeneic organ transplant (including bone marrow or stem cells);

          -  Has, within the past 10 years, had evidence of or required treatment for cancer
             (except treated basal or squamous cell carcinoma of the skin or cured cervical
             carcinoma-in-situ);

          -  Has had within the past three months or is expected to have during the study period
             any of the following treatments:

          -  surgery requiring general anesthesia

          -  hematopoietic stimulating agents (e.g., erythropoietin, G-CSF, GM-CSF)

          -  another investigational drug;

          -  Has other significant medical disease (chronic or active within the past 6 months),
             including, but not limited to: cardiac disease (e.g., unstable angina, myocardial
             infarction, congestive heart failure, ventricular arrhythmia); uncontrolled seizure
             disorder; liver disease; chronic infection (e.g., tuberculosis); uncontrolled
             diabetes;

          -  Has any other condition that would, in the opinion of the Investigator, potentially
             compromise the safety or compliance of the patient or may preclude the patient's
             successful completion of the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D Arbeit, MD</last_name>
    <role>Study Director</role>
    <affiliation>Idera Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Center for Dermatology, P.A</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center, PC</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Specialists, Inc.</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital Clinical Unit for Research Trials in Skin</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, Inc</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Dermatology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>May 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
